Cargando…

Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer

BACKGROUND: Aberrant choline metabolism has been proposed as a novel cancer hallmark. We recently showed that epithelial ovarian cancer (EOC) possesses an altered MRS-choline profile, characterised by increased phosphocholine (PCho) content to which mainly contribute over-expression and activation o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Granata, A, Nicoletti, R, Tinaglia, V, De Cecco, L, Pisanu, M E, Ricci, A, Podo, F, Canevari, S, Iorio, E, Bagnoli, M, Mezzanzanica, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899765/ https://www.ncbi.nlm.nih.gov/pubmed/24281000 http://dx.doi.org/10.1038/bjc.2013.729

Ejemplares similares

Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy
por: Pisanu, M E, et al.
Publicado: (2014)

Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma
por: Granata, Anna, et al.
Publicado: (2015)

Choline Metabolism Alteration: A Focus on Ovarian Cancer
por: Bagnoli, Marina, et al.
Publicado: (2016)

Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells
por: Rizzo, Andrea, et al.
Publicado: (2021)

In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer
por: Canese, Rossella, et al.
Publicado: (2016)

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo
por: Bapiro, T E, et al.
Publicado: (2014)

Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model
por: Paris, Luisa, et al.
Publicado: (2017)

Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs
por: Ridolfi, E, et al.
Publicado: (2008)

Effect of Pantethine on Ovarian Tumor Progression and Choline Metabolism
por: Penet, Marie-France, et al.
Publicado: (2016)

Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients
por: Bagnoli, Marina, et al.
Publicado: (2011)

Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients
por: Bagnoli, Marina, et al.
Publicado: (2011)

Profilin-1 is a negative regulator of mammary carcinoma aggressiveness
por: Zou, L, et al.
Publicado: (2007)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Detection of polyol accumulation in a new ovarian carcinoma cell line, CABA I: a(1)H NMR study
por: Ferretti, A, et al.
Publicado: (2002)

Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection
por: Fu, Yi-Peng, et al.
Publicado: (2016)

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
por: Nutt, J E, et al.
Publicado: (2010)

MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity
por: Cebulla, J, et al.
Publicado: (2015)

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors
por: Engerud, H, et al.
Publicado: (2014)

Activation of Phosphatidylcholine-Specific Phospholipase C in Breast and Ovarian Cancer: Impact on MRS-Detected Choline Metabolic Profile and Perspectives for Targeted Therapy
por: Podo, Franca, et al.
Publicado: (2016)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study
por: Köbel, M, et al.
Publicado: (2014)

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer
por: Coley, H M, et al.
Publicado: (2012)

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma
por: White, N M A, et al.
Publicado: (2009)

Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers
por: Sereni, Maria Isabella, et al.
Publicado: (2017)

The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome
por: Kumar, S R, et al.
Publicado: (2007)

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
por: Wilbaux, M, et al.
Publicado: (2014)

Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors
por: Ajani, Jaffer A, et al.
Publicado: (2018)

Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation
por: Minas, V, et al.
Publicado: (2007)

Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition
por: Duran, George E, et al.
Publicado: (2017)

Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis
por: Duiker, E W, et al.
Publicado: (2011)

Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer
por: Zeng, C, et al.
Publicado: (2013)

Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging
por: Vassileva, V, et al.
Publicado: (2008)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
por: Peasland, A, et al.
Publicado: (2011)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
por: Glaysher, S, et al.
Publicado: (2010)

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
por: Vaidyanathan, Aparajitha, et al.
Publicado: (2016)

Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment
por: Taylor-Harding, B, et al.
Publicado: (2012)

In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring
por: Zhong, W, et al.
Publicado: (2009)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m11qshe5iuf1grn0j1b8t1u5e4